CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net restructuring and other special charges	$ 8.6	$ 12.6
Operating Income (Loss)	341.0	687.9
Interest Expense	50.7	42.2
Equity method income, net	(2.1)	3.4
Investment income	2.2	1.1
Other, net	(12.6)	(10.1)
Earnings before income taxes	277.8	640.1
Provision for income taxes	64.5	148.0
Net earnings	213.3	492.1
Net Income (Loss) Attributable to Noncontrolling Interest	0.4	0.5
Net Income (Loss) Attributable to Parent	212.9	491.6
Revenues	3,777.9	3,899.6
Cost of Revenue	2,803.2	2,666.7
Gross Profit	974.7	1,232.9
Selling, general and administrative expenses	553.6	464.1
Amortization of intangibles and other assets	69.3	67.1
Asset Impairment Charges	2.2	1.2
Revenues	3,777.9	3,899.6
Cost of Revenue	2,803.2	2,666.7
Gross Profit	974.7	1,232.9
Selling, general and administrative expenses	553.6	464.1
Amortization of intangibles and other assets	69.3	67.1
Asset Impairment Charges	2.2	1.2
Net restructuring and other special charges	8.6	12.6
Operating Income (Loss)	341.0	687.9
Other income (expenses):
Interest expense	(50.7)	(42.2)
Equity method income, net	(2.1)	3.4
Investment income	2.2	1.1
Other, net	(12.6)	(10.1)
Earnings before income taxes	277.8	640.1
Provision for income taxes	64.5	148.0
Net earnings	213.3	492.1
Less: Net earnings attributable to the noncontrolling interest	(0.4)	(0.5)
Net earnings attributable to Laboratory Corporation of America Holdings	$ 212.9	$ 491.6
Basic earnings per common share (in dollars per share)	$ 2.41	$ 5.27
Diluted earnings per common share (in dollars per share)	$ 2.39	$ 5.23